Patent 7364736

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (4)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2003-02-04 · reel 009230/0173 · Assignment

    Boyle, William J.; Martin, Francis H.AMGEN INC.

    Correspondent: R. Brian Drozd · AMGEN INC.

    internal reorg

  2. 2003-02-04 · reel 009230/0173 · Assignment

    Davis, C. Geoffrey; Corvalan, Jose R.ABGENIX, INC.

    Correspondent: R. Brian Drozd · AMGEN INC.

    internal reorg

  3. 2007-12-07 · reel 020613/0349 · Merger

    ABGENIX, INC.AMGEN FREMONT INC.

    Correspondent: R. Brian Drozd · AMGEN INC.

    acquisition

  4. 2022-09-26 · reel 059952/0970 · Assignment

    AMGEN FREMONT INC.AMGEN INC.

    Correspondent: R. Brian Drozd · AMGEN INC.

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • William J. Boyle (Amgen Inc.)
  • Francis H. Martin (Amgen Inc.)
  • Jose R. Corvalan (Abgenix Inc.)
  • C. Geoffrey Davis (Abgenix Inc.)

Original assignee

The original assignees listed on the application were Amgen Inc. and Amgen Fremont Inc.. Amgen Inc. is a multinational biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics. They have historically shipped products embodying similar claims. Amgen is currently an operating company.

Assignment timeline

  • 2003-02-04 (executed) / recorded 2003-02-04 — Reel 009230/0173

    • Conveyance: Assignment
    • Assignor: Boyle, William J.; Martin, Francis H.
    • Assignee: AMGEN INC.
    • Correspondent: R. Brian Drozd, AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320-1789.
    • Context: Internal reorg (assignment from inventors to corporate entity)

  • 2003-02-04 (executed) / recorded 2003-02-04 — Reel 009230/0173

    • Conveyance: Assignment
    • Assignor: Davis, C. Geoffrey; Corvalan, Jose R.
    • Assignee: ABGENIX INC.
    • Correspondent: R. Brian Drozd, AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320-1789. This correspondent also appears on the Amgen Inc. assignment.
    • Context: Internal reorg (assignment from inventors to corporate entity)

  • 2007-12-07 (executed) / recorded 2007-12-07 — Reel 020613/0349

    • Conveyance: Merger
    • Assignor: ABGENIX, INC.
    • Assignee: AMGEN FREMONT INC.
    • Correspondent: R. Brian Drozd, AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320-1789. This correspondent also appears on the previous assignments.
    • Context: Acquisition (Abgenix acquired by Amgen)

  • 2022-09-26 (executed) / recorded 2022-09-26 — Reel 059952/0970

    • Conveyance: Assignment
    • Assignor: AMGEN FREMONT INC.
    • Assignee: AMGEN INC.
    • Correspondent: R. Brian Drozd, AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320-1789. This correspondent also appears on the previous assignments.
    • Context: Internal reorg

Timeline diagram

timeline
    title Ownership of US 7364736
    2002 : Filed by Amgen Inc & Amgen Fremont Inc
    2003 : Inventors Boyle/Martin assigned to Amgen Inc
         : Inventors Davis/Corvalan assigned to Abgenix Inc
    2007 : Abgenix Inc merged into Amgen Fremont Inc
    2008 : Issued
    2022 : Amgen Fremont Inc assigned to Amgen Inc

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. All assignees appear to be operating companies (Amgen Inc., Abgenix Inc., Amgen Fremont Inc.).
  2. Known asserter in the chain — not present. None of the listed assignees are identified as known NPEs.
  3. Repeat correspondent across the chain — present. R. Brian Drozd of Amgen Inc. is the correspondent for all recorded assignments: Reel 009230/0173 (2003-02-04), Reel 020613/0349 (2007-12-07), and Reel 059952/0970 (2022-09-26).
  4. Cascading transfers — not present. The assignments are spaced years apart.
  5. Pre-litigation transfer — unclear. While the patent family has litigation, this analysis focuses on the specific patent US7364736. Without specific litigation filing dates for US7364736, it's unclear if the 2022 assignment precedes litigation within a 6-month window.
  6. Bankruptcy fire-sale — not present. There is no indication of bankruptcy for Amgen or Abgenix in the assignment records.
  7. Privateering — not present. No evidence of privateering has been identified.
  8. Defensive aggregator (anti-NPE) — not present. The current assignee is Amgen Inc., an operating company.

Verdict

Operating-company assertion. The assignment records clearly show the patent has remained within the Amgen corporate family, including the acquisition of Abgenix Inc. by Amgen Fremont Inc., and subsequent internal transfers. The consistent correspondent, R. Brian Drozd of Amgen Inc., further supports this internal management of the patent portfolio. Therefore, the patent is likely used by an operating company against actual competitors.
(Verification: https://assignmentcenter.uspto.gov/)

Generated 5/29/2026, 8:40:39 PM